Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Cytiva is investing 500 million USD over five years to expand manufacturing capacity, supporting growth in the biotechnology sector. The initiative aligns with rising industry demand, particularly accelerated by COVID-19. The company plans to hire nearly 1,000 personnel globally, enhancing its operational efficiency through new manufacturing lines and increased automation. Key expansions include tripling single-use technology capacity in Asia-Pacific and doubling chromatography product platform capacity in Sweden. This investment aims to ensure a secure supply chain and support the rapidly growing cell and gene therapy market.
Danaher Corporation (NYSE: DHR) announced the appointment of Rainer M. Blair as the new President and Chief Executive Officer, effective September 1, 2020. This follows the retirement of Thomas P. Joyce, Jr., who will continue to support the company as a senior advisor until February 28, 2021. The succession plan aims to ensure leadership continuity and maintain Danaher's commitment to innovation in health care and environmental sectors. Danaher operates over 20 companies and employs more than 67,000 associates worldwide.
Beckman Coulter launched its Access SARS-CoV-2 Immunoglobulin M (IgM) assay to enhance COVID-19 testing capabilities. This IgM test achieved 99.9% specificity and 98.3% sensitivity at 15-30 days post-symptom onset, making it highly effective. Unlike other tests, it targets antibodies against the receptor binding domain of the spike protein, potentially neutralizing the virus. The company can deliver over 15 million tests monthly and is also developing additional assays, including IgG and interleukin 6 tests, to further assist healthcare providers in diagnosing COVID-19.
Summary not available.
Danaher Corporation (NYSE: DHR) has announced its second-quarter 2020 earnings conference call scheduled for July 23, 2020, at 8:00 a.m. ET. The call will be accessible via a webcast on Danaher's website, where an accompanying slide presentation will also be available. A replay of the call will remain accessible until August 6, 2020. Danaher is known for its innovation in science and technology with a strong presence in health care and environmental sectors, underpinned by the Danaher Business System.